Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Dec 21, 2013; 19(47): 8895-8901
Published online Dec 21, 2013. doi: 10.3748/wjg.v19.i47.8895
Published online Dec 21, 2013. doi: 10.3748/wjg.v19.i47.8895
Effects of antiviral therapy on preventing liver tumorigenesis and hepatocellular carcinoma recurrence
Zhong-Ming Tan, Bei-Cheng Sun, Liver Transplantation Center of the First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, Jiangsu Province, China
Zhong-Ming Tan, Bei-Cheng Sun, The Key Laboratory of Living Donor Liver Transplantation, Ministry of Health, Nanjing 210029, Jiangsu Province, China
Author contributions: Tan ZM and Sun BC wrote the paper, Sun BC designed and supervised the work.
Correspondence to: Bei-Cheng Sun, MD, PhD, Liver Transplantation Center of the First Affiliated Hospital, Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, Jiangsu Province, China. sunbc@njmu.edu.cn
Telephone: +86-25-68136746 Fax: +86-25-86560946
Received: September 9, 2013
Revised: October 28, 2013
Accepted: November 18, 2013
Published online: December 21, 2013
Revised: October 28, 2013
Accepted: November 18, 2013
Published online: December 21, 2013
Core Tip
Core tip: Chronic hepatitis B virus (HBV) infection is the key driving force of hepatocellular carcinoma (HCC). In this review, we discussed the mechanism of HBV induction of HCC and described the current trends in anti-HBV therapy. The associations of anti-HBV therapy with prevention of HCC incidence and recurrence after curative operations were also summarized. Moreover, based on our center’s experiences, a standardized antiviral strategy was suggested which greatly benefited those patients who underwent hepatectomy and liver transplantation with regard to better clinical results.